Figure 5. Excretion of S-[2-(fluoromethoxy)-1,1,3,3,3-pentafluoropropyl]-N-acetyl-L-cysteine (compound 3) and [acetyl-(²) H³]S-[2-(fluoromethoxy)-1,1,3,3,3 -pentafluoropropyl]-N-acetyl-L-cysteine (compound 3-d³) in rats given [acetyl-(²) H³]S-[2-(fluoromethoxy)-1,3,3,3-tetrafluoro-1-propenyl]-N-acetyl-L-cysteine and of S-[2-(fluoromethoxy)-1,3,3,3-tetrafluoro-1-propenyl]-N-acetyl-L -cysteine (compound 5) and [acetyl-(²) H³]S-[2(fluoromethoxy)-1,3,3,3 -tetrafluoro-1-propenyl]-N-acetyl-L-cysteine (compound 5-d³) in rats given [acetyl-(²) H³]S-[2-(fluoromethoxy)-1,3,3,3-tetrafluoro-1-propenyl]-N-acetyl-L-cysteine. Rats were given 125 [micro sign]mol/kg compound 3-d³or 5-d³intraperitoneally, and the fraction of the administered dose excreted from 0-24 h as compounds 3 and 3-d³or compounds 5 and 5-d³, respectively, was quantified by gas chromatography--mass spectrometry, as described in the Materials and Methods section. Data are shown as mean +/− SEM (n = 3).